The development of a drug is a long process that requires more than 10 years and 1 billion of dollars.
We are therefore committed to fast forward the development of new therapies and improve their accessibility for more people in the world by
contributing in the discovery of new biomarkers and targets to develop innovative therapeutics
advancing our understanding of cell metabolism that is central to almost all diseases (cancers, diabetes, microbiota dysbiosis, metabolic inborn errors, …)
democratising AI and digital twins to optimise bioprocesses and address Industry 4.0 challenges in pharmas and biotechs
Agronomy is the key to meeting the challenges of feeding fast-growing populations, ecology and climate change.
We are committed to developing collaborative digital tools and digital twin technologies to
facilitate the agro-ecologic transition of agro-technology companies
improve our understanding of host-pathogen interactions to better protect crops
decipher and predict the adverse effects of crop-protection solutions on humans and animals.
Nutrition
Nutrition plays a central role in the health and well-being of humans and animals. In such a context, microorganisms are increasingly used in the development of nutritional products (probiotics, food supplements, flavourings and tasting products, …)
We provide technologies to build and use digital twins of cell metabolism, called digital organisms, which are the ideal proxy for modelling and predicting, in silico, the behaviour of microorganisms.
We are continuously exploring new frontiers to provide valuable digital solutions to accelerate R&D in biotechnology industries where micro-organisms are used (waste biodegradation, carbon capture, biofuel, …)
